查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2059307

自動化類器官培養市場：市場洞察、競爭格局與市場預測（2034 年）

Automated Organoid Culturing - Market Insights, Competitive Landscape, and Market Forecast - 2034
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

自動化類器官培養市場概述

  • 全球自動化類器官培養市場預計將從 2025 年的 4.2098 億美元成長到 2034 年的 12.5772 億美元，顯示其成長強勁且持續。
  • 全球自動化類器官培養市場預計在 2026 年至 2034 年的預測期內將以 13.04% 的年複合成長率成長。
  • 自動化類器官培養市場主要受三大關鍵因素的共同推動，這些因素正在改變生物醫學研究和藥物發現的模式。首先，對先進3D細胞培養模式的需求日益成長，促使研究人員拋棄傳統的2D系統。類器官在藥物發現和疾病建模的預測研究中發揮著極其重要的作用，因為它們能夠更精確地模擬人體組織的結構和生理反應。其次，個人化醫療的日益普及推動了對病患來源類器官的需求。這使得臨床醫生和研究人員能夠利用個人化的生物模型檢驗藥物反應，從而提高治療的精準度，尤其是在腫瘤學和罕見疾病領域。第三，自動化和人工智慧（AI）技術的進步正在整合機器人技術、基於AI的成像技術和數據分析，從而實現可擴展、可重複且高通量的類器官生產，顯著降低人工操作的差異性和營運成本。這些因素共同作用，將類器官研究從人工操作、低通量的實驗室流程轉變為標準化、工業規模的平台，這極大地推動了自動化類器官培養市場的成長。
  • 在自動化類器官培養市場中營運的主要公司包括：Molecular Devices LLC、Advanced Solutions Life Sciences LLC、Galatek、Addimus Bio、InSphero AG、Thermo Fisher Scientific Inc.、Sartorius AG、Tecan Group Ltd.、Hamilton Company、Revvity Inc.、Danaher Corporation、Corningal Technologies Corporation Ltd. SE、Beckman Coulter Life Sciences（Danaher Corporation）、Yokogawa Electric Corporation、Curi Bio Inc.、Emulate Inc.、CN Bio Innovations Ltd.、Mimetas BV 和 TissUse GmbH。
  • 北美地區預計將引領自動化類器官培養市場的發展，這得益於其強大的生物技術和製藥生態系統、先進的實驗室自動化技術普及率高，以及在藥物研發和再生醫學領域的大量投入。該地區匯集了許多領先的研究機構和成熟的生物製藥公司，以及大量致力於開發自動化細胞培養和類器官平台的技術供應商。此外，政府資助、人工智慧驅動的實驗工作流程的早期應用，以及對高通量、可重複體外模型日益成長的需求，都進一步推動了該地區的市場成長。
  • 在自動化類器官培養市場的產品和服務領域，預計到 2025 年，耗材類別將佔據最大的市場佔有率。

推動自動化類器官培養市場成長的因素

  • 對先進3D細胞培養模型日益成長的需求正推動著自動化類器官培養的蓬勃發展。傳統的2D細胞培養無法精確模擬人體真實的生理功能，因此迫切需要更具預測性的模型。類器官是能夠忠實模擬人體器官結構和功能的3D結構，使其在藥物研發和疾病研究上具有極高的價值。自動化能夠實現標準化和規模化生產，進一步提升了類器官的效用，這對於工業應用至關重要。
  • 個人化醫療中自動化類器官培養技術的廣泛應用：自動化類器官培養在個人化醫療中發揮至關重要的作用，尤其是在患者來源類器官方面。這些模型使研究人員能夠在臨床治療前，並利用單一患者細胞測試多種治療方法。自動化技術確保了快速的處理速度、結果的一致性以及同時處理多個患者樣本的能力，從而在腫瘤學和罕見疾病治療領域中迅速應用。
  • 自動化和人工智慧技術的進步：自動化和人工智慧技術的進步顯著推動了自動化類器官培養市場的發展，提高了複雜生物實驗的效率、擴充性和可重複性。自動化流體處理系統、機器人培養平台以及人工智慧驅動的成像和數據分析技術，能夠精確控制類器官的生長條件，同時減少人為誤差和變異性。此外，人工智慧演算法支援對類器官發育進行即時監測、模式識別和預測建模，從而加速藥物篩檢和疾病建模過程。自動化和人工智慧的協同效應正在將類器官研究轉變為高通量、標準化且更具成本效益的工作流程，從而促使製藥和生物技術公司進一步採用這些技術。

自動化類器官培養市場報告細分

這份自動化類器官培養市場報告全面概​​述了全球自動化類器官培養市場，揭示了關鍵趨勢、成長要素、挑戰和機會。報告涵蓋了詳細的市場細分，包括產品和服務（設備、耗材、服務）、類器官（胰臟、腸道、肝臟、肺臟、神經等）、應用（疾病病理學、再生醫學、藥物測試、藥物發現和個人化醫療等）、最終用戶（製藥和生物技術公司、合約研究組織 (CRO) 等）以及地區。報告深入分析了北美、歐洲和亞太等主要市場的競爭格局、監管環境和市場動態，並詳細介紹了主要行業參與者和近期產品創新，為企業提供關鍵數據，以識別市場潛力、制定戰略計劃並把握快速成長的自動化類器官培養市場中的新興機遇。

自動化類器官培養是指利用先進的機器人系統、實驗室自動化平台和數位技術，對類器官（由幹細胞建構的3D微組織模型）進行培養、維護和分析。該過程最大限度地減少了細胞接種、培養基更換、培養管理、監測和成像等步驟中的人工干預，與手動方法相比，確保了更高的準確性、可重複性和擴充性。透過將自動化與軟體驅動的控制以及在某些情況下基於人工智慧的分析相結合，自動化類器官培養能夠穩定地生產用於藥物發現、疾病建模和個人化醫療研究的複雜生物模型。

自動化類器官培養市場主要受三大關鍵因素的共同推動，這些因素正在改變現代生物醫學研究和藥物發現。首先，對先進3D細胞培養模型的需求日益成長，正促使研究方法從傳統的2D細胞系統轉向3D細胞系統。類器官能夠更精確地模擬人體組織結構、細胞多樣性和生理功能的關鍵特徵，因此在臨床前藥物測試、毒性測試和疾病建模方面具有顯著更高的預測準確性。這種改進的生物驗證正在推動其在製藥業和學術研究領域的應用。

其次，個人化醫療的興起顯著加速了病患來源類器官的應用。這些模型由患者自身的細胞建構而成，使研究人員和臨床醫生能夠評估特定藥物在患者獨特的生物環境中的反應。這在腫瘤學、罕見遺傳疾病和精準醫療領域尤其重要，因為這些領域的治療效果因人而異。隨著醫學向更具針對性和個性化的治療策略轉變，對這類個人化類器官模型的需求正在迅速成長。

第三，自動化和人工智慧（AI）技術的快速發展正將類器官培養轉變為可擴展且標準化的流程。諸如機器人流體處理系統、培養箱和微流體平台等自動化系統減少了人工干預，而人工智慧驅動的成像和分析技術則實現了對類器官生長和行為的即時監測、品管和預測性評估。這些技術不僅提高了可重複性並減少了人為誤差，還顯著提高了通量並降低了營運成本。這三大因素共同推動類器官研究從勞動密集、低通量的實驗室技術轉向高效率的工業級平台轉變，從而有力地促進了自動化類器官培養市場的成長。

自動化類器官培養市場的最新市場動態和趨勢是什麼？

對先進3D細胞培養模型日益成長的需求正顯著加速自動化類器官培養市場的成長。這是因為研究人員擴大採用類器官作為傳統2D細胞培養的替代方案，因為類器官能夠更真實地再現人體組織的結構、功能和生物學複雜性。這些3D系統在藥物和生物醫學研究中具有極高的價值，因為它們在疾病建模、毒性測試和藥物篩檢方面能夠提供更符合生理學的結果。然而，手動類器官培養勞動密集、耗時且容易出現變異，限制了其規模化應用。這項挑戰正推動自動化平台的快速普及，這些平台能夠標準化培養條件、提高可重複性並實現類器官的高通量生產。

近期的技術進步進一步加速了這一趨勢。例如，2025年12月，CellXpress.ai的自動化細胞培養系統在埃默里大學腦類器官中心投入使用。該系統旨在自動化細胞營養供應、培養、成像和數據分析等複雜且重複的流程，從而實現類器官數週至數月的連續培養，且只需極少的人工干預。該平台還強調其能夠同時培養數千個類器官，並利用人工智慧成像技術追蹤細胞增殖和分化模式，從而提高實驗的一致性和可重複性。

此外，個人化醫療的日益普及是推動自動化類器官培養市場發展的主要動力。這是因為個人化醫療正在將醫療保健從「千篇一律」的治療模式轉向高度個人化的治療策略。這種方法涉及利用特定患者的細胞培養患者來源的類器官（PDO），從而建立其器官或腫瘤的微型模型。這使得忠實地再現患者獨特的遺傳和生物學特徵成為可能。這些類器官使研究人員能夠直接在患者特異性模型上測試多種藥物，有助於預測治療反應、確定最有效的治療方法，並減少臨床決策中的試驗誤。因此，對可擴展且可重複的類器官生產的需求日益成長，推動了能夠處理高通量生產、降低變異性並整合基於人工智慧的分析以更快地獲得治療見解的自動化培養系統的應用。近期的發展進一步凸顯了這個趨勢。例如，2025年11月，臨床研究人員報告稱，基於類器官的平台在腫瘤學領域得到越來越廣泛的應用，用於指導化療和免疫療法的選擇，並指出它們通過構建患者特異性腫瘤模型來改善個性化癌症治療的效果。因此，上述因素預計將在預測期內推動整個自動化類器官培養市場的成長。

然而，高昂的初始投資成本、資料管理挑戰以及對人工智慧的依賴是限制自動化類器官培養市場發展的主要阻礙因素。先進的自動化平台、機器人、成像系統和整合人工智慧軟體都需要大量的前期投資，這使得小規模的研究機構和實驗室難以採用這些技術。此外，自動化系統會產生大量複雜的生物學和影像數據，需要強大的儲存基礎設備、強大的運算能力以及用於分析的複雜人工智慧模型。數據處理精度或人工智慧解釋的任何不足都可能影響實驗結果和可重複性。這些因素共同導致了操作複雜性和成本的增加，阻礙了自動化類器官培養系統的廣泛應用。

自動化類器官培養市場的市場區隔

按產品/服務（設備、耗材、服務）、類器官（胰臟、腸道、肝臟、肺臟、神經系統等）、應用（疾病病理學、再生醫學、藥物測試、藥物發現和個人化醫療等）、最終用戶（製藥和生物技術公司、合約研究組織 (CRO) 等）以及地區（北美、歐洲、亞太地區、世界其他地區）進行分類。

自動化類器官培養市場區域分析

北美自動化類器官培養市場趨勢

預計到2025年，北美將佔據自動化類器官培養市場41%的最大佔有率，成為全球最大的地區。北美預計將主導自動化類器官培養市場，這得益於其高度發展的生物醫學研究生態系統、眾多領先企業的強大影響力，以及對機器人驅動的3D細胞培養系統、微流體技術和人工智慧驅動的自動化平台等最尖端科技的快速應用。該地區受益於製藥和生物技術公司的大量研發投入、政府和私人機構對再生醫學和精準醫學研究的廣泛資助，以及緊密的產學研合作網路，這些都促進了基於類器官的模型在藥物發現和毒性測試工作流程中的快速應用。

此外，北美在早期採用高通量自動化類器官生產系統、整合 3D 成像和類器官檢測以及擴大使用患者來源的類器官進行個性化醫療應用方面發揮了主導作用，進一步鞏固了該地區的市場主導地位。

總體而言，北美的主導地位源於強大的研發資金、高度集中的領先生物技術和生命科學公司、快速的技術整合（自動化、人工智慧、微流體技術）以及透過併購和產品發布不斷創新，這些因素正在加速自動化類器官培養系統在藥物發現、疾病建模和個人化醫療領域的應用。

歐洲自動化類器官培養市場趨勢

歐洲自動化類器官培養市場正經歷強勁且持續的成長，這主要得益於3D細胞培養技術的快速發展、類器官模型在藥物研發和毒性測試中日益廣泛的應用，以及精準醫療和再生醫學研究中對生理相關人類疾病模型的需求不斷成長。歐洲擁有高度協作的研究環境，這得益於領先的學術機構、生物技術新創公司和成熟的生命科學公司，以及旨在減少動物實驗和加速先進治療方法開發的強力的政府資助。此外，該地區正在加速整合基於自動化人工智慧影像分析和微流體技術的類器官平台，顯著提高了類器官生產流程的可重複性、擴充性和通量。因此，歐洲仍然是類器官創新最重要的中心之一，佔據全球市場的重要佔有率，預計在預測期內將以兩位數的中段年複合成長率高速成長。

主要市場參與企業的近期發展活動進一步凸顯了這一成長趨勢。 2024年3月，CHA Biotech與Cell in Cells合作，共同開發基於類器官的軟骨疾病再生醫學療法，反映出歐洲對類器官研究臨床應用的日益濃厚的興趣。此外，他們也透過銷售合作，致力於提升實驗室自動化球狀體和類器官平台的可近性，進而擴大類器官和3D細胞培養的商業化進程。這些進展，加上歐洲企業的持續創新，正在推動晶片器官系統和標準化類器官培養基的研發，以支援自動化和高通量篩檢應用。

總體而言，這些策略擴張、收購和合作正在加速自動化類器官培養技術在歐洲的普及，鞏固了歐洲作為高成長區域市場的地位，而這一成長得益於對創新、轉化研究和替代測試模型的強力的監管支持。

亞太地區自動化類器官培養市場趨勢

亞太地區正崛起為自動化類器官培養市場的主要驅動力，這主要得益於生物技術研究投入的增加、製藥產能的快速擴張，以及中國、日本、韓國和印度等國家對先進3D細胞培養技術的日益普及。政府對再生醫學、精準醫療和藥物研發創新的大力支持，以及學術機構與生技公司之間合作的加強，正在加速類器官研究的發展。此外，慢性病和癌症的日益普遍也推動了對更具可預測性和類人生物特徵的臨床前模型的需求，進而促進了自動化類器官系統的應用。合約研究組織（CRO）數量的成長、成本效益高的研發基礎設施以及對人工智慧整合實驗室自動化的日益關注，進一步鞏固了亞太地區在該市場高成長區域的地位。

自動化類器官培養市場的主要參與者有哪些？

以下是自動化類器官培養市場的主要參與者。這些公司合計佔據最大的市場佔有率，並引領產業趨勢。

  • Molecular Devices LLC
  • Advanced Solutions Life Sciences LLC
  • Galatek
  • Addimus Bio
  • InSphero AG
  • Thermo Fisher Scientific Inc.
  • Sartorius AG
  • Tecan Group Ltd.
  • Hamilton Company
  • Revvity Inc.
  • Danaher Corporation
  • Corning Incorporated
  • STEMCELL Technologies Inc.
  • Greiner Bio-One International GmbH
  • Eppendorf SE
  • Beckman Coulter Life Sciences (Danaher Corporation)
  • Yokogawa Electric Corporation
  • Curi Bio Inc.
  • Emulate Inc.
  • CN Bio Innovations Ltd.
  • Mimetas BV
  • TissUse GmbH
  • 其他

自動化類器官培養市場的競爭模式是如何形成的？

自動化類器官培養市場的競爭格局日益集中，並向創新主導成長轉型。少數幾家全球生命科學巨頭和專業生物技術公司共同塑造市場格局。賽默飛世爾科技、康寧公司、賽多利斯公司和默克集團等領導企業憑藉其強大的細胞培養基、生物反應器、支架和實驗室自動化系統產品組合，主導著市場，這些產品組合直接支持可擴展的類器官生產。這些公司利用其先進的研發能力、全球分銷網路以及與製藥和生物技術公司建立的穩固關係，將大規模的類器官工作流程整合到藥物發現和轉化研究流程中。

除了這些成熟的公司之外，InSphero AG、HUB Organoids、Emulate 和 STEMCELL Technologies 等高度專業化的類器官公司也透過提供疾病特異性類器官模型、患者來源的系統以及針對精準醫療和毒性測試最佳化的先進 3D 培養平台，不斷鞏固其市場地位。這些參與企業特定領域的公司不僅在規模上競爭，更主要透過技術差異化來取勝，例如晶片器官整合、自動化相容性和更高的生物學保真度。

同時，新創公司和新興生技公司正透過推出經濟高效的自動化平台、微流體系統和人工智慧整合的培養工作流程，加劇競爭，挑戰傳統的手動和半自動化系統。此外，越來越多的合約研究組織 (CRO) 和合約開發與受託製造廠商(CDMO) 進入市場，幫助製藥公司擴大類器官在藥物研發中的應用，進一步拓展了生態系統，加劇了競爭。整體而言，競爭格局正朝著自動化、標準化和可擴展的方向顯著轉變，併購和策略聯盟已成為企業拓展技術組合、鞏固其在快速發展的類器官培養生態系統中地位的關鍵策略。

自動化類器官培養市場的最新趨勢

  • 2026 年 4 月，TheWell Bioscience 宣布推出“通用無異種類器官培養基”，旨在規範類器官培養條件，降低長期 3D 細胞培養實驗的成本和變異性。
  • 2026 年 2 月，Bio-Techne 推出了 Cultrex™ 合成水凝膠，這是一種完全定義的細胞外基質 (ECM)，專門為 3D 幹細胞和類器官培養而設計。
  • 2025 年 12 月，CellXpress.ai 自動化細胞培養系統安裝在埃默里大學腦類器官中心。

自動化類器官培養市場的市場區隔

  • 自動化類器官培養市場（依產品和服務分類）
  • 裝置
  • 消耗品
  • 服務
  • 自動化類器官培養中類器官的分類
  • 胰臟
  • 腸子
  • 胰臟和腸道
  • 肺
  • 神經
  • 其他
  • 引入自動化類器官培養應用程式
  • 疾病和病理
  • 再生醫學
  • 藥物發現
  • 藥物發現與個人化醫療
  • 其他
  • 接觸自動化類器官培養的最終用戶
  • 製藥和生物技術公司
  • 受託研究機構（CRO）
  • 其他
  • 自動化類器官培養的區域趨勢
  • 北美自動化類器官培養市場
  • 美國自動化類器官培養市場
  • 加拿大自動化類器官培養市場
  • 墨西哥自動化類器官培養市場
  • 歐洲自動化類器官培養市場
  • 英國自動化類器官培養市場
  • 德國自動化類器官培養市場
  • 法國自動化類器官培養市場
  • 義大利自動化類器官培養市場
  • 西班牙自動化類器官培養市場
  • 其他歐洲市場對自動化類器官培養的需求
  • 亞太地區自動化類器官培養市場
  • 中國自動化類器官培養市場
  • 日本自動化類器官培養市場
  • 印度自動化類器官培養市場
  • 澳洲自動化類器官培養市場
  • 韓國自動化類器官培養市場
  • 亞太地區其他自動化類器官培養市場
  • 世界其他地區的自動化類器官培養市場
  • 南美洲自動化類器官培養市場
  • 中東自動化類器官培養市場
  • 非洲自動化類器官培養市場

影響分析

人工智慧驅動的創新與應用：

人工智慧驅動的自動化類器官培養創新正在改變這一領域，實現完全自主的實驗工作流程、預測建模和高解析度生物學決策。目前，機器學習和深度學習系統已整合到自動化細胞培養平台中，即時控制類器官的接種、補料、傳代和成熟等流程，並持續分析影像資料以動態調整實驗條件。這些人工智慧系統能夠自動進行影像分割、形態分析和活力評估，使研究人員能夠在極少人工干預的情況下準確分類類器官的生長模式和藥物反應。人工智慧也被應用於預測性藥物篩檢和毒性評估，訓練後的模型分析大規模類器官資料集，預測特定化合物在類人組織中的行為，從而顯著提高藥物發現流程的效率。

此外，新興的人工智慧驅動的「封閉回路型」系統結合了機器人技術、成像技術和反饋演算法，提高了培養的標準化和可重複性，因為類器官的生長結果直接影響下一步的實驗。諸如數位雙胞胎和「虛擬類器官」等更先進的概念也正在湧現，它們透過計算模型模擬類器官發育來指導物理實驗，從而降低成本並縮短實驗時間。總而言之，人工智慧正在將自動化類器官培養從一種手動實驗室技術轉變為一個自我最佳化、數據驅動的生物工程平台，從而加速疾病建模、個人化醫療和高通量藥物發現。

美國關稅對自動化類器官培養市場的影響分析：

美國關稅對自動化類器官培養市場的影響主要體現在進口實驗室設備、耗材、生物反應器、微流體裝置和先進細胞培養材料的成本增加，而這些設備嚴重依賴全球供應鏈，尤其是來自歐洲和亞洲的供應鏈。由於類器官自動化中使用的許多關鍵組件，例如液體處理系統、3D支架、微孔盤、成像系統和生物反應器組件，均在美國境外生產，因此關稅增加了美國國內生物技術公司和研究機構的採購和生產成本。這將推高類器官培養平台的終端用戶價格，從而減緩成本敏感型學術和臨床研究機構的採用。同時，整體生命科學領域普遍存在的情況一樣，關稅正促使企業採取供應鏈多元化、近岸外包和增加實驗室自動化工具的國內生產等措施。在該領域，企業正在將投資轉移到美國國內生產，以避免進口關稅並降低地緣政治風險。

此外，關稅導致的成本增加間接影響了藥物研發和個人化醫療的進度，因為自動化類器官系統對於高通量篩檢和毒性測試至關重要。企業可能會透過建立策略聯盟、實現類器官平台在地化生產或重新設計產品以增加對國內耗材的依賴來應對這項挑戰。總體而言，關稅環境正在為整個自動化類器官培養生態系統帶來短期價格壓力，同時也透過加速供應鏈在地化、促進主要參與者之間的垂直整合以及推動具成本效益自動化技術的創新來重塑市場格局。

這項分析能為客戶帶來哪些好處？

  • 成本管理：透過了解關稅趨勢，客戶可以預測成本上漲，並據此調整定價策略，以確保盈利。
  • 供應鏈最佳化：透過尋找替代供應商並實現供應鏈多元化，客戶可以減少對高關稅地區的依賴，增強自身抵禦能力。
  • 監管合規：專家指導幫助客戶應對不斷變化的法規環境，從而保持合規並避免潛在的法律挑戰。
  • 策略規劃：深入了解關稅的影響，使客戶能夠就製造地、夥伴關係和打入市場策略做出明智的決策。

自動化類器官培養市場報告研究要點

  • 自動化類器官培養市場目前市場規模分析（2025 年）及 8 年市場預測（2026 年至 2034 年）
  • 過去三年發生的主要產品和技術開發、併購、合作和合資企業
  • 引領自動化類器官培養市場的領導企業。
  • 自動化類器官培養市場為其他競爭對手提供了各種機會。
  • 哪些細分市場在2025年表現最佳？這些細分市場在2034年又會呈現哪些趨勢？
  • 目前哪些地區、國家在自動化類器官培養市場表現最佳？
  • 企業應專注於哪些地區和國家，以尋求自動化類器官培養市場的未來成長機會？

關於自動化類器官培養市場的常見問題

1. 自動化類器官培養市場的成長率是多少？

  • 預計從 2026 年到 2034 年的預測期內，自動化類器官培養市場將以 13.04% 的年複合成長率成長。

2. 自動化類器官培養市場規模有多大？

  • 全球自動化類器官培養市場預計將從 2025 年的 4.2098 億美元成長到 2034 年的 12.5772 億美元。

3. 哪個地區在自動化類器官培養市場中佔據最大的市場佔有率？

  • 北美地區預計將引領自動化類器官培養市場的發展，這得益於其強大的生物技術和製藥生態系統、先進的實驗室自動化技術普及率高，以及在藥物研發和再生醫學領域的大量投入。該地區匯集了許多領先的研究機構和成熟的生物製藥公司，以及大量致力於開發自動化細胞培養和類器官平台的技術供應商。此外，政府資助、人工智慧驅動的實驗工作流程的早期應用，以及對高通量、可重複體外模型日益成長的需求，都進一步推動了該地區的市場成長。

4. 自動化類器官培養市場的成長要素是什麼？

  • 自動化類器官培養市場主要受三大關鍵因素的共同推動，這些因素正在改變生物醫學研究和藥物發現的模式。首先，對先進3D細胞培養模式的需求日益成長，促使研究人員拋棄傳統的2D系統。類器官在藥物發現和疾病建模的預測研究中具有不可估量的價值，因為它們能夠更精確地模擬人體組織的結構和生理反應。其次，個人化醫療的日益普及推動了對病患來源類器官的需求成長。這使得臨床醫生和研究人員能夠利用個人化的生物模型檢驗藥物反應，從而提高治療的準確性，尤其是在腫瘤學和罕見疾病領域。第三，自動化和人工智慧（AI）技術的進步正在整合機器人技術、基於AI的成像技術和數據分析，從而實現可擴展、可重複且高通量的類器官生產，顯著降低人工操作的差異性和營運成本。這些因素共同作用，使類器官研究從人工操作、低通量的實驗室流程轉變為標準化、工業規模的平台，這極大地推動了自動化類器官培養市場的成長。

5. 在自動化類器官培養市場中營運的主要公司有哪些？

  • 自動化類器官培養市場的主要參與企業包括 Molecular Devices LLC、Advanced Solutions Life Sciences LLC、Galatek、Addimus Bio、InSphero AG、Thermo Fisher Scientific Inc.、Sartorius AG、Tecan Group Ltd.、Hamilton Company、Revvity Inc.、Danaher Corporation、Corning Incorporated、A.D.B. Coulter Life Sciences（Danaher Corporation）、Yokogawa Electric Corporation、Curi Bio Inc.、Emulate Inc.、CN Bio Innovations Ltd.、Mimetas BV 和 TissUse GmbH。

目錄

第1章：自動化類器官培養市場報告概述

第2章：自動化類器官培養市場執行摘要

第3章：自動化類器官培養市場關鍵因素分析

  • 自動化類器官培養市場促進因素
    • 對先進3D細胞培養模型的需求日益成長
    • 個人化醫療的普及
    • 自動化和人工智慧領域的技術進步
  • 自動化類器官培養市場的限制與挑戰
    • 初始設定費用相當高。
    • 資料管理和人工智慧依賴性問題
  • 自動化類器官培養市場的機遇
    • 類器官在組織修復、移植研究和器官替代療法的應用

第4章：影響分析

  • 人工智慧驅動的創新和應用
  • 美國關稅影響分析

第5章：監理分析

  • 美國
  • 歐洲
  • 日本
  • 中國

第6章：波特五力模型對自動化類器官培養市場的分析

第7章：自動化類器官培養市場評估

  • 按產品/服務
    • 裝置
    • 消耗品
    • 服務
  • 透過類器官
    • 胰臟
    • 腸子
    • 肝
    • 肺
    • 神經
    • 其他
  • 透過使用
    • 疾病病理
    • 再生醫學
    • 藥物檢測
    • 藥物發現與個人化醫療
  • 最終用戶
    • 製藥和生物技術公司
    • 醫藥研發合約組織（CRO）
  • 按地區
    • 北美洲
    • 歐洲
    • 亞太地區
    • 其他地區

第8章 競爭情勢

第9章：新創企業資金籌措與投資趨勢

第10章：自動化類器官培養市場－公司與產品概況

  • Molecular Devices LLC
  • Advanced Solutions Life Sciences LLC
  • Galatek
  • Addimus Bio
  • InSphero AG
  • Thermo Fisher Scientific Inc.
  • Sartorius AG
  • Tecan Group Ltd.
  • Hamilton Company
  • Revvity Inc. (formerly PerkinElmer)
  • Danaher Corporation
  • Corning Incorporated
  • STEMCELL Technologies Inc.
  • Greiner Bio-One International GmbH
  • Eppendorf SE
  • Beckman Coulter Life Sciences (Danaher Corporation)
  • Yokogawa Electric Corporation
  • Curi Bio Inc.
  • Emulate Inc.
  • CN Bio Innovations Ltd.

第11章：KOL的觀點

第12章 專案方法

第13章：關於 DelveInsight

第14章 免責聲明與聯絡方式

Product Code: DIMDCL0922

Automated Organoid Culturing Market Summary

  • The global automated organoid culturing market is expected to increase from USD 420.98 million in 2025 to USD 1,257.72 million by 2034, reflecting strong and sustained growth.
  • The global automated organoid culturing market is growing at a CAGR of 13.04% during the forecast period from 2026 to 2034.
  • The market for Automated Organoid Culturing is being strongly driven by the convergence of three key factors that are transforming biomedical research and drug development. First, the rising demand for advanced 3D cell culture models is pushing researchers away from conventional 2D systems, as organoids more accurately replicate human tissue architecture and physiological responses, making them highly valuable for predictive studies in drug discovery and disease modeling. Second, the increasing adoption of personalized medicine is accelerating demand for patient-derived organoids, which allow clinicians and researchers to test drug responses on individualized biological models, improving treatment precision, especially in oncology and rare diseases. Third, technological advancements in automation and artificial intelligence are enabling scalable, reproducible, and high-throughput organoid production by integrating robotics, AI-based imaging, and data analytics, significantly reducing manual variability and operational costs. Collectively, these factors are transforming organoid research from a manual, low-throughput laboratory process into a standardized, industrial-scale platform, thereby significantly boosting the growth of the automated organoid culturing market.
  • The leading companies operating in the automated organoid culturing market include Molecular Devices LLC, Advanced Solutions Life Sciences LLC, Galatek, Addimus Bio, InSphero AG, Thermo Fisher Scientific Inc., Sartorius AG, Tecan Group Ltd., Hamilton Company, Revvity Inc., Danaher Corporation, Corning Incorporated, STEMCELL Technologies Inc., Greiner Bio-One International GmbH, Eppendorf SE, Beckman Coulter Life Sciences (Danaher Corporation), Yokogawa Electric Corporation, Curi Bio Inc., Emulate Inc., CN Bio Innovations Ltd., Mimetas B.V., TissUse GmbH, and others.
  • North America is expected to dominate the automated organoid culturing market due to its strong biotechnology and pharmaceutical ecosystem, high adoption of advanced laboratory automation, and significant R&D investments in drug discovery and regenerative medicine. The region is home to leading research institutions, well-established biopharma companies, and a high concentration of technology providers developing automated cell culture and organoid platforms. Additionally, supportive government funding, early adoption of AI-driven lab workflows, and increasing demand for high-throughput, reproducible in-vitro models further strengthen market growth in the region.
  • In the product and services segment of the automated organoid culturing market, the consumables category is estimated to account for the largest market share in 2025.

Factors Contributing to the Growth of the Automated Organoid Culturing Market

  • Rising demand for advanced 3D cell culture models is leading to a surge in automated organoid culturing: Traditional 2D cell cultures fail to replicate real human physiology, which creates a strong need for more predictive models. Organoids, being 3D structures that closely mimic human organ architecture and function, are highly valuable in drug discovery and disease research. Automation further enhances their usability by enabling standardized and scalable production, which is critical for industrial applications.
  • Increasing adoption in personalized medicine: Automated organoid culturing is playing a pivotal role in Personalized Medicine, particularly through patient-derived organoids. These models allow researchers to test multiple therapies on an individual patient's cells before clinical treatment. Automation ensures rapid turnaround time, consistency, and the ability to handle multiple patient samples simultaneously, driving strong adoption in oncology and rare disease treatment.
  • Technological Advancements in Automation and AI: Technological advancements in automation and AI are significantly boosting the automated organoid culturing market by improving efficiency, scalability, and reproducibility of complex biological experiments. Automated liquid handling systems, robotic culture platforms, and AI-driven imaging and data analytics enable precise control of organoid growth conditions while reducing manual errors and variability. AI algorithms further help in real-time monitoring, pattern recognition, and predictive modeling of organoid development, accelerating drug screening and disease modeling processes. Together, automation and AI are transforming organoid research into a high-throughput, standardized, and more cost-effective workflow, driving broader adoption across pharmaceutical and biotechnology companies.

Automated Organoid Culturing Market Report Segmentation

This automated organoid culturing market report offers a comprehensive overview of the global automated organoid culturing market, highlighting key trends, growth drivers, challenges, and opportunities. It covers detailed market segmentation by Product and Services (Instruments, Consumables, and Services), Organoids (Pancreas, Intestine, Liver, Lung, Neural, and Others), Application (Disease Pathology, Regenerative Medicine, Drug Testing, Drug Discovery And Personalized Medicine, and Others), End-Users (Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs), and Others), and geography. The report provides valuable insights into the competitive landscape, regulatory environment, and market dynamics across major markets, including North America, Europe, and Asia-Pacific. Featuring in-depth profiles of leading industry players and recent product innovations, this report equips businesses with essential data to identify market potential, develop strategic plans, and capitalize on emerging opportunities in the rapidly growing Automated Organoid Culturing market.

Automated organoid culturing refers to the use of advanced robotic systems, laboratory automation platforms, and digital technologies to grow, maintain, and analyze organoids, three-dimensional miniaturized tissue models derived from stem cells. In this process, steps such as cell seeding, media exchange, incubation control, monitoring, and imaging are performed with minimal human intervention, ensuring higher precision, reproducibility, and scalability compared to manual methods. By integrating automation with software-driven controls and sometimes AI-based analytics, automated organoid culturing enables consistent production of complex biological models used in drug discovery, disease modeling, and personalized medicine research.

The market for automated organoid culturing is being strongly driven by the convergence of three major factors that are reshaping modern biomedical research and drug development. Firstly, the growing demand for advanced 3D cell culture models is shifting research practices away from traditional 2D cell systems. Organoids are able to replicate key aspects of human tissue architecture, cellular diversity, and physiological function more accurately, making them far more predictive for preclinical drug testing, toxicity studies, and disease modeling. This improved biological relevance is increasing their adoption across pharmaceutical and academic research settings.

Secondly, the rise of personalized medicine is significantly accelerating the use of patient-derived organoids. These models are created from individual patients' cells and allow researchers and clinicians to evaluate how specific drugs will respond in a patient-specific biological environment. This is particularly valuable in oncology, rare genetic disorders, and precision therapeutics, where treatment outcomes vary widely among individuals. As healthcare moves toward more targeted and personalized treatment strategies, demand for such individualized organoid models is expanding rapidly.

Thirdly, rapid advancements in automation and artificial intelligence are transforming organoid culturing into a scalable and standardized process. Automated systems such as robotic liquid handlers, incubators, and microfluidic platforms reduce manual intervention, while AI-powered imaging and analytics enable real-time monitoring, quality control, and predictive assessment of organoid growth and behavior. These technologies not only enhance reproducibility and reduce human error but also significantly improve throughput and reduce operational costs. Collectively, these three drivers are converting organoid research from a labor-intensive, low-throughput laboratory technique into a highly efficient, industrial-scale platform, thereby strongly propelling the growth of the automated organoid culturing market.

What are the latest automated organoid culturing market dynamics and trends?

The rising demand for advanced 3D cell culture models is significantly accelerating the growth of the automated organoid culturing market because researchers are increasingly replacing traditional 2D cell cultures with organoids that better mimic the structural, functional, and biological complexity of human tissues. These 3D systems provide more physiologically relevant results for disease modeling, toxicity testing, and drug screening, which have made them highly valuable in pharmaceutical and biomedical research. However, manual organoid cultivation is labor-intensive, time-consuming, and prone to variability, which limits scalability. This challenge is driving strong adoption of automated platforms that can standardize culture conditions, improve reproducibility, and enable high-throughput production of organoids.

Recent technological developments further reinforce this trend. For example, in December 2025, the CellXpress.ai automated cell culture system at Emory University's Brain Organoid Hub was installed. The system was designed to automate complex and repetitive steps such as cell feeding, incubation, imaging, and data analysis, allowing organoids to be cultured continuously for weeks or even months with minimal human intervention. It was also highlighted that the platform could culture thousands of organoids simultaneously while using AI-based imaging to track cell growth and differentiation patterns, improving consistency and reproducibility in experiments.

Additionally, the increasing adoption of personalized medicine is significantly boosting the automated organoid culturing market because it shifts healthcare from a "one-size-fits-all" approach to highly individualized treatment strategies. In this approach, patient-derived organoids (PDOs) are grown from a specific patient's cells to create miniature models of their organs or tumors, which closely replicate their unique genetic and biological characteristics. These organoids allow researchers to test multiple drugs directly on a patient-specific model, helping predict treatment response, identify the most effective therapy, and reduce trial-and-error in clinical decision-making. As a result, demand for scalable and reproducible organoid production is rising, driving adoption of automated culturing systems that can handle high-throughput generation, reduce variability, and integrate AI-based analysis for faster therapeutic insights. Recent developments further highlight this trend. For instance, in November 2025, clinical researchers reported expanding use of organoid-based platforms in oncology to guide chemotherapy and immunotherapy selection, improving personalized cancer treatment outcomes through patient-specific tumor modelling. Thus, the factors mentioned above are expected to boost the overall market of automated organoid culturing during the forecast period.

However, the high initial setup costs, data management, and AI dependency issues are acting as key limiting factors for the automated organoid culturing market. The requirement for advanced automation platforms, robotics, imaging systems, and AI-integrated software leads to substantial upfront investment, making it difficult for smaller research institutes and laboratories to adopt these technologies. Additionally, automated systems generate large volumes of complex biological and imaging data that require robust storage infrastructure, high computational power, and sophisticated AI models for analysis. Any limitations in data processing accuracy or AI interpretation can affect experimental outcomes and reproducibility. Together, these factors increase operational complexity and cost burdens, thereby restraining the broader adoption of automated organoid culturing systems.

Automated Organoid Culturing Market Segment Analysis

Automated Organoid Culturing Market by Product and Services (Instruments, Consumables, and Services), Organoids (Pancreas, Intestine, Liver, Lung, Neural, and Others), Application (Disease Pathology, Regenerative Medicine, Drug Testing, Drug Discovery And Personalized Medicine, and Others), End-Users (Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs), and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

Automated Organoid Culturing Market Regional Analysis

North America Automated Organoid Culturing Market Trends

North America is expected to account for the highest proportion of 41% of the automated organoid culturing market in 2025, out of all regions. North America is expected to dominate the automated organoid culturing market due to its highly advanced biomedical research ecosystem, strong presence of leading life sciences companies, and rapid adoption of cutting-edge technologies such as robotics-enabled 3D cell culture systems, microfluidics, and AI-driven automated platforms. The region benefits from substantial R&D investments by pharmaceutical and biotechnology companies, extensive government and private funding for regenerative medicine and precision medicine research, and a dense network of academic-industry collaborations that accelerate translation of organoid-based models into drug discovery and toxicology testing workflows.

Additionally, North America leads in early adoption of high-throughput automated organoid production systems, integration of 3D imaging with organoid assays, and increasing use of patient-derived organoids for personalized medicine applications, which further strengthens its market dominance.

Overall, the dominance of North America is driven by the convergence of strong R&D funding, high concentration of leading biotech and life science companies, rapid technological integration (automation, AI, microfluidics), and continuous innovation through mergers, acquisitions, and product launches that collectively accelerate the adoption of automated organoid culturing systems across drug discovery, disease modeling, and personalized medicine.

Europe Automated Organoid Culturing Market Trend

The automated organoid culturing market in Europe is witnessing strong and sustained growth, driven by rapid advancements in 3D cell culture technologies, increasing adoption of organoid-based models in drug discovery and toxicology testing, and rising demand for physiologically relevant human disease models in precision medicine and regenerative medicine research. Europe benefits from a highly collaborative research environment supported by leading academic institutions, biotech startups, and established life science companies, alongside strong government funding initiatives aimed at reducing animal testing and accelerating advanced therapy development. The region is also experiencing increasing integration of automation, AI-driven image analysis, and microfluidics-based organoid platforms, which are significantly improving reproducibility, scalability, and throughput in organoid production workflows. As a result, Europe remains one of the most important hubs for organoid innovation, accounting for a substantial share of the global market and expected to grow at a high double-digit CAGR over the forecast period.

Recent development activities by key market players further highlight this growth trajectory. In March 2024, CHA Biotech entered into a collaboration with Cell in Cells to develop organoid-based regenerative therapies for cartilage diseases, reflecting Europe's increasing focus on clinical translation of organoid research. In addition, expanded its organoid and 3D cell culture commercialization efforts through distribution partnerships aimed at improving access to automated spheroid and organoid platforms across research laboratories. These developments are complemented by continuous innovation from European-based companies, which are advancing organ-on-chip systems and standardized organoid culture media to support automation and high-throughput screening applications.

Collectively, these strategic expansions, acquisitions, and collaborations are accelerating the adoption of automated organoid culturing technologies across Europe, reinforcing its position as a high-growth regional market driven by innovation, translational research, and strong regulatory support for alternative testing models.

Asia-Pacific Automated Organoid Culturing Market Trends

The Asia Pacific (APAC) region is emerging as a major growth driver for the automated organoid culturing market due to increasing investments in biotechnology research, rapid expansion of pharmaceutical manufacturing capabilities, and growing adoption of advanced 3D cell culture technologies across countries such as China, Japan, South Korea, and India. The region is witnessing strong government support for regenerative medicine, precision medicine, and drug discovery innovation, along with rising collaborations between academic institutions and biotech companies that are accelerating organoid-based research. Additionally, the increasing prevalence of chronic diseases and cancer is driving demand for more predictive and human-relevant preclinical models, boosting the adoption of automated organoid systems. The presence of expanding contract research organizations (CROs), cost-effective R&D infrastructure, and growing focus on AI-integrated laboratory automation further strengthens APAC's position as a high-growth region in this market.

Who are the major players in the automated organoid culturing market?

The following are the leading companies in the automated organoid culturing market. These companies collectively hold the largest market share and dictate industry trends.

  • Molecular Devices LLC
  • Advanced Solutions Life Sciences LLC
  • Galatek
  • Addimus Bio
  • InSphero AG
  • Thermo Fisher Scientific Inc.
  • Sartorius AG
  • Tecan Group Ltd.
  • Hamilton Company
  • Revvity Inc.
  • Danaher Corporation
  • Corning Incorporated
  • STEMCELL Technologies Inc.
  • Greiner Bio-One International GmbH
  • Eppendorf SE
  • Beckman Coulter Life Sciences (Danaher Corporation)
  • Yokogawa Electric Corporation
  • Curi Bio Inc.
  • Emulate Inc.
  • CN Bio Innovations Ltd.
  • Mimetas B.V.
  • TissUse GmbH
  • Others

How is the competitive landscape shaping the automated organoid culturing market?

The competitive landscape of the automated organoid culturing market is moderately consolidated and increasingly innovation-driven, where a small group of global life science giants and specialized biotech firms collectively shape market direction. Large players such as Thermo Fisher Scientific, Corning Incorporated, Sartorius AG, and Merck KGaA dominate due to their strong portfolios in cell culture media, bioreactors, scaffolds, and laboratory automation systems that directly support scalable organoid production. These companies benefit from deep R&D capabilities, global distribution networks, and established relationships with pharmaceutical and biotech customers, allowing them to integrate organoid workflows into drug discovery and translational research pipelines at scale.

Alongside these incumbents, highly specialized organoid-focused firms such as InSphero AG, HUB Organoids, Emulate, and STEMCELL Technologies are strengthening their positions by offering disease-specific organoid models, patient-derived systems, and advanced 3D culture platforms tailored for precision medicine and toxicity testing. These niche players compete primarily through technological differentiation, such as organ-on-chip integration, automation compatibility, and improved biological fidelity rather than scale alone.

At the same time, startups and emerging biotech companies are intensifying competition by introducing cost-effective automated platforms, microfluidic systems, and AI-integrated culturing workflows, which are challenging traditional manual and semi-automated systems. The market is also seeing growing involvement from contract research organizations (CROs) and CDMOs, which are helping pharmaceutical companies scale organoid use in drug discovery, further expanding the ecosystem and increasing competitive density. Overall, the competitive landscape is being shaped by a clear shift toward automation, standardization, and scalability, with mergers, acquisitions, and strategic collaborations becoming key strategies for companies to expand technology portfolios and strengthen their positions in the rapidly evolving organoid cultivation ecosystem.

Recent Developmental Activities in the Automated Organoid Culturing Market

  • In April 2026, TheWell Bioscience introduced a Universal Xeno-Free Organoid Medium, designed to standardize organoid culture conditions and reduce cost and variability in long-term 3D cell culture experiments.
  • In February 2026, Bio-Techne launched the Cultrex(TM) Synthetic Hydrogel, a fully defined extracellular matrix (ECM) designed specifically for 3D stem cell and organoid cultures.
  • In December 2025, the CellXpress.ai automated cell culture system at Emory University's Brain Organoid Hub was installed.

Automated Organoid Culturing Market Segmentation

  • Automated Organoid Culturing by Product and Services Exposure
  • Instruments
  • Consumables
  • Services
  • Automated Organoid Culturing Organoid Exposure
  • Pancreas
  • Intestine
  • Liver
  • Lung
  • Neural
  • Others
  • Automated Organoid Culturing Application Exposure
  • Disease Pathology
  • Regenerative Medicine
  • Drug Testing
  • Drug Discovery and Personalized Medicine
  • Others
  • Automated Organoid Culturing End-Users Exposure
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Others
  • Automated Organoid Culturing Geography Exposure
  • North America Automated Organoid Culturing Market
  • United States Automated Organoid Culturing Market
  • Canada Automated Organoid Culturing Market
  • Mexico Automated Organoid Culturing Market
  • Europe Automated Organoid Culturing Market
  • United Kingdom Automated Organoid Culturing Market
  • Germany Automated Organoid Culturing Market
  • France Automated Organoid Culturing Market
  • Italy Automated Organoid Culturing Market
  • Spain Automated Organoid Culturing Market
  • Rest of Europe Automated Organoid Culturing Market
  • Asia-Pacific Automated Organoid Culturing Market
  • China Automated Organoid Culturing Market
  • Japan Automated Organoid Culturing Market
  • India Automated Organoid Culturing Market
  • Australia Automated Organoid Culturing Market
  • South Korea Automated Organoid Culturing Market
  • Rest of Asia-Pacific Automated Organoid Culturing Market
  • Rest of the World Automated Organoid Culturing Market
  • South America Automated Organoid Culturing Market
  • Middle East Automated Organoid Culturing Market
  • Africa Automated Organoid Culturing Market

Impact Analysis

AI-Powered Innovations and Applications:

AI-powered innovations in automated organoid culturing are transforming the field by enabling fully autonomous experimental workflows, predictive modeling, and high-resolution biological decision-making. Machine learning and deep learning systems are now being integrated into automated cell culture platforms to control processes such as organoid seeding, feeding, passaging, and maturation in real time, while continuously analyzing imaging data to adjust experimental conditions dynamically. These AI systems can perform automated image segmentation, morphological profiling, and viability assessment, allowing researchers to classify organoid growth patterns and drug responses with high accuracy and minimal human intervention. AI is also being used for predictive drug screening and toxicity evaluation, where trained models analyze large-scale organoid datasets to forecast how specific compounds will behave in human-like tissues, significantly improving the efficiency of drug discovery pipelines.

Additionally, emerging AI-driven "closed-loop" systems combine robotics, imaging, and feedback algorithms, where organoid growth outcomes directly influence the next experimental step, making cultures more standardized and reproducible. More advanced concepts, such as digital twin or "virtual organoids," are also emerging, where computational models simulate organoid development and guide physical experiments, reducing cost and experimental time. Overall, AI is shifting automated organoid culturing from a manual laboratory technique into a self-optimizing, data-driven biological engineering platform that accelerates disease modeling, personalized medicine, and high-throughput drug development.

U.S. Tariff Impact Analysis on Automated Organoid Culturing Market:

The U.S. tariff impact on the automated organoid culturing market is primarily reflected through rising costs of imported laboratory instruments, consumables, bioreactors, microfluidic devices, and advanced cell culture materials that are heavily dependent on global supply chains, especially from Europe and Asia. Since many key components used in organoid automation, such as liquid handling systems, 3D scaffolds, microplates, imaging systems, and bioreactor parts, are manufactured outside the U.S., tariffs increase procurement and production costs for both domestic biotech companies and research institutions. This leads to higher end-user prices for organoid culture platforms and slower adoption in cost-sensitive academic and clinical research settings. At the same time, tariffs are encouraging companies to adopt supply chain diversification, nearshoring, and increased domestic manufacturing of lab automation tools, as seen broadly across the life sciences sector, where firms are shifting investments toward U.S.-based production to avoid import duties and reduce geopolitical risk.

In addition, tariff-driven cost inflation is indirectly affecting R&D timelines in drug discovery and personalized medicine, since automated organoid systems are critical for high-throughput screening and toxicity testing. Companies may respond by forming strategic partnerships, localizing manufacturing of organoid platforms, or redesigning products to rely more on domestically sourced consumables. Overall, the tariff environment is reshaping the market by accelerating regionalization of supply chains, increasing vertical integration among leading players, and pushing innovation in cost-efficient automation technologies, while also creating short-term pricing pressure across the automated organoid culturing ecosystem.

How This Analysis Helps Clients

  • Cost Management: By understanding the tariff landscape, clients can anticipate cost increases and adjust pricing strategies accordingly, ensuring profitability.
  • Supply Chain Optimization: Clients can identify alternative sourcing options and diversify their supply chains to reduce dependency on high-tariff regions, enhancing resilience.
  • Regulatory Navigation: Expert guidance on navigating the evolving regulatory environment helps clients maintain compliance and avoid potential legal challenges.
  • Strategic Planning: Insights into tariff impacts enable clients to make informed decisions about manufacturing locations, partnerships, and market entry strategies.

Key takeaways from the automated organoid culturing market report study

  • Market size analysis for the current automated organoid culturing market size (2025), and market forecast for 8 years (2026 to 2034)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
  • Key companies dominating the automated organoid culturing market.
  • Various opportunities available for the other competitors in the automated organoid culturing market space.
  • What are the top-performing segments in 2025? How these segments will perform in 2034?
  • Which are the top-performing regions and countries in the current automated organoid culturing market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for the automated organoid culturing market growth in the future.

Frequently Asked Questions for the Automated Organoid Culturing Market

1. What is the growth rate of the automated organoid culturing market?

  • The automated organoid culturing market is estimated to grow at a CAGR of 13.04% during the forecast period from 2026 to 2034.

2. What is the market for automated organoid culturing?

  • The global automated organoid culturing market is expected to increase from USD 420.98 million in 2025 to USD 1,257.72 million by 2034.

3. Which region has the highest share in the automated organoid culturing market?

  • North America is expected to dominate the automated organoid culturing market due to its strong biotechnology and pharmaceutical ecosystem, high adoption of advanced laboratory automation, and significant R&D investments in drug discovery and regenerative medicine. The region is home to leading research institutions, well-established biopharma companies, and a high concentration of technology providers developing automated cell culture and organoid platforms. Additionally, supportive government funding, early adoption of AI-driven lab workflows, and increasing demand for high-throughput, reproducible in-vitro models further strengthen market growth in the region.

4. What are the drivers for the automated organoid culturing market?

  • The market for Automated Organoid Culturing is being strongly driven by the convergence of three key factors that are transforming biomedical research and drug development. First, the rising demand for advanced 3D cell culture models is pushing researchers away from conventional 2D systems, as organoids more accurately replicate human tissue architecture and physiological responses, making them highly valuable for predictive studies in drug discovery and disease modeling. Second, the increasing adoption of personalized medicine is accelerating demand for patient-derived organoids, which allow clinicians and researchers to test drug responses on individualized biological models, improving treatment precision, especially in oncology and rare diseases. Third, technological advancements in automation and artificial intelligence are enabling scalable, reproducible, and high-throughput organoid production by integrating robotics, AI-based imaging, and data analytics, significantly reducing manual variability and operational costs. Collectively, these factors are transforming organoid research from a manual, low-throughput laboratory process into a standardized, industrial-scale platform, thereby significantly boosting the growth of the automated organoid culturing market.

5. Who are the key players operating in the automated organoid culturing market?

  • Some of the key market players operating in the automated organoid culturing market include Molecular Devices LLC, Advanced Solutions Life Sciences LLC, Galatek, Addimus Bio, InSphero AG, Thermo Fisher Scientific Inc., Sartorius AG, Tecan Group Ltd., Hamilton Company, Revvity Inc., Danaher Corporation, Corning Incorporated, STEMCELL Technologies Inc., Greiner Bio-One International GmbH, Eppendorf SE, Beckman Coulter Life Sciences (Danaher Corporation), Yokogawa Electric Corporation, Curi Bio Inc., Emulate Inc., CN Bio Innovations Ltd., Mimetas B.V., TissUse GmbH, and others.

Table of Contents

1. Automated Organoid Culturing Market Report Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Segmentation
  • 1.3 Market Assumption

2. Automated Organoid Culturing Market Executive Summary

  • 2.1 Market at Glance

3. Automated Organoid Culturing Market Key Factors Analysis

  • 3.1 Automated Organoid Culturing Market Drivers
    • 3.1.1 Rising demand for advanced 3D cell culture models
    • 3.1.2 Increasing adoption in personalized medicine
    • 3.1.3 Technological advancements in automation and AI
  • 3.2 Automated Organoid Culturing Market Restraints and Challenges
    • 3.2.1 High initial setup cost
    • 3.2.2 Data management and AI dependency issues
  • 3.3 Automated Organoid Culturing Market Opportunity
    • 3.3.1 Use of organoids for tissue repair, transplantation research, and organ replacement therapies

4. Impact Analysis

  • 4.1 AI-Powered Innovations and Applications
  • 4.2 U.S. Tariff Impact Analysis

5. Regulatory Analysis

  • 5.1 The United States
  • 5.2 Europe
  • 5.3 Japan
  • 5.4 China

6. Automated Organoid Culturing Market Porter's Five Forces Analysis

  • 6.1 Bargaining Power of Suppliers
  • 6.2 Bargaining Power of Consumers
  • 6.3 Threat of New Entrants
  • 6.4 Threat of Substitutes
  • 6.5 Competitive Rivalry

7. Automated Organoid Culturing Market Assessment

  • 7.1 By Product and Services
    • 7.1.1 Instruments
    • 7.1.2 Consumables
    • 7.1.3 Services
  • 7.2 By Organoid
    • 7.2.1 Pancreas
    • 7.2.2 Intestine
    • 7.2.3 Liver
    • 7.2.4 Lung
    • 7.2.5 Neural
    • 7.2.6 Others
  • 7.3 By Application
    • 7.3.1 Disease Pathology
    • 7.3.2 Regenerative Medicine
    • 7.3.3 Drug Testing
    • 7.3.4 Drug Discovery And Personalized Medicine
    • 7.3.5 Others
  • 7.4 By End-Users
    • 7.4.1 Pharmaceutical & Biotechnology Companies
    • 7.4.2 Contract Research Organizations (CROs)
    • 7.4.3 Others
  • 7.5 By Geography
    • 7.5.1 North America
      • 7.5.1.1 United States Automated Organoid Culturing Market Size in USD million (2023-2034)
      • 7.5.1.2 Canada Automated Organoid Culturing Market Size in USD million (2023-2034)
      • 7.5.1.3 Mexico Automated Organoid Culturing Market Size in USD million (2023-2034)
    • 7.5.2 Europe
      • 7.5.2.1 France Automated Organoid Culturing Market Size in USD million (2023-2034)
      • 7.5.2.2 Germany Automated Organoid Culturing Market Size in USD million (2023-2034)
      • 7.5.2.3 United Kingdom Automated Organoid Culturing Market Size in USD million (2023-2034)
      • 7.5.2.4 Italy Automated Organoid Culturing Market Size in USD million (2023-2034)
      • 7.5.2.5 Spain Automated Organoid Culturing Market Size in USD million (2023-2034)
      • 7.5.2.6 Rest of Europe Automated Organoid Culturing Market Size in USD million (2023-2034)
    • 7.5.3 Asia-Pacific
      • 7.5.3.1 China Automated Organoid Culturing Market Size in USD million (2023-2034)
      • 7.5.3.2 Japan Automated Organoid Culturing Market Size in USD million (2023-2034)
      • 7.5.3.3 India Automated Organoid Culturing Market Size in USD million (2023-2034)
      • 7.5.3.4 Australia Automated Organoid Culturing Market Size in USD million (2023-2034)
      • 7.5.3.5 South Korea Automated Organoid Culturing Market Size in USD million (2023-2034)
      • 7.5.3.6 Rest of Asia-Pacific Automated Organoid Culturing Market Size in USD million (2023-2034)
    • 7.5.4 Rest of the World (RoW)
      • 7.5.4.1 Middle East Automated Organoid Culturing Market Size in USD million (2023-2034)
      • 7.5.4.2 Africa Automated Organoid Culturing Market Size in USD million (2023-2034)
      • 7.5.4.3 South America Automated Organoid Culturing Market Size In USD Million (2023-2034)

8. Competitive Landscape

9. Startup Funding & Investment Trends

10. Automated Organoid Culturing Market Company and Product Profiles

  • 10.1 Molecular Devices LLC
    • 10.1.1 Company Overview
    • 10.1.2 Company Snapshot
    • 10.1.3 Financial Overview
    • 10.1.4 Product Listing
    • 10.1.5 Entropy
  • 10.2 Advanced Solutions Life Sciences LLC
    • 10.2.1 Company Overview
    • 10.2.2 Company Snapshot
    • 10.2.3 Financial Overview
    • 10.2.4 Product Listing
    • 10.2.5 Entropy
  • 10.3 Galatek
    • 10.3.1 Company Overview
    • 10.3.2 Company Snapshot
    • 10.3.3 Financial Overview
    • 10.3.4 Product Listing
    • 10.3.5 Entropy
  • 10.4 Addimus Bio
    • 10.4.1 Company Overview
    • 10.4.2 Company Snapshot
    • 10.4.3 Financial Overview
    • 10.4.4 Product Listing
    • 10.4.5 Entropy
  • 10.5 InSphero AG
    • 10.5.1 Company Overview
    • 10.5.2 Company Snapshot
    • 10.5.3 Financial Overview
    • 10.5.4 Product Listing
    • 10.5.5 Entropy
  • 10.6 Thermo Fisher Scientific Inc.
    • 10.6.1 Company Overview
    • 10.6.2 Company Snapshot
    • 10.6.3 Financial Overview
    • 10.6.4 Product Listing
    • 10.6.5 Entropy
  • 10.7 Sartorius AG
    • 10.7.1 Company Overview
    • 10.7.2 Company Snapshot
    • 10.7.3 Financial Overview
    • 10.7.4 Product Listing
    • 10.7.5 Entropy
  • 10.8 Tecan Group Ltd.
    • 10.8.1 Company Overview
    • 10.8.2 Company Snapshot
    • 10.8.3 Financial Overview
    • 10.8.4 Product Listing
    • 10.8.5 Entropy
  • 10.9 Hamilton Company
    • 10.9.1 Company Overview
    • 10.9.2 Company Snapshot
    • 10.9.3 Financial Overview
    • 10.9.4 Product Listing
    • 10.9.5 Entropy
  • 10.10 Revvity Inc. (formerly PerkinElmer)
    • 10.10.1 Company Overview
    • 10.10.2 Company Snapshot
    • 10.10.3 Financial Overview
    • 10.10.4 Product Listing
    • 10.10.5 Entropy
  • 10.11 Danaher Corporation
    • 10.11.1 Company Overview
    • 10.11.2 Company Snapshot
    • 10.11.3 Financial Overview
    • 10.11.4 Product Listing
    • 10.11.5 Entropy
  • 10.12 Corning Incorporated
    • 10.12.1 Company Overview
    • 10.12.2 Company Snapshot
    • 10.12.3 Financial Overview
    • 10.12.4 Product Listing
    • 10.12.5 Entropy
  • 10.13 STEMCELL Technologies Inc.
    • 10.13.1 Company Overview
    • 10.13.2 Company Snapshot
    • 10.13.3 Financial Overview
    • 10.13.4 Product Listing
    • 10.13.5 Entropy
  • 10.14 Greiner Bio-One International GmbH
    • 10.14.1 Company Overview
    • 10.14.2 Company Snapshot
    • 10.14.3 Financial Overview
    • 10.14.4 Product Listing
    • 10.14.5 Entropy
  • 10.15 Eppendorf SE
    • 10.15.1 Company Overview
    • 10.15.2 Company Snapshot
    • 10.15.3 Financial Overview
    • 10.15.4 Product Listing
    • 10.15.5 Entropy
  • 10.16 Beckman Coulter Life Sciences (Danaher Corporation)
    • 10.16.1 Company Overview
    • 10.16.2 Company Snapshot
    • 10.16.3 Financial Overview
    • 10.16.4 Product Listing
    • 10.16.5 Entropy
  • 10.17 Yokogawa Electric Corporation
    • 10.17.1 Company Overview
    • 10.17.2 Company Snapshot
    • 10.17.3 Financial Overview
    • 10.17.4 Product Listing
    • 10.17.5 Entropy
  • 10.18 Curi Bio Inc.
    • 10.18.1 Company Overview
    • 10.18.2 Company Snapshot
    • 10.18.3 Financial Overview
    • 10.18.4 Product Listing
    • 10.18.5 Entropy
  • 10.19 Emulate Inc.
    • 10.19.1 Company Overview
    • 10.19.2 Company Snapshot
    • 10.19.3 Financial Overview
    • 10.19.4 Product Listing
    • 10.19.5 Entropy
  • 10.20 CN Bio Innovations Ltd.
    • 10.20.1 Company Overview
    • 10.20.2 Company Snapshot
    • 10.20.3 Financial Overview
    • 10.20.4 Product Listing
    • 10.20.5 Entropy

11. KOL Views

12. Project Approach

13. About DelveInsight

14. Disclaimer & Contact Us

List of Tables

  • Table 1: Automated Organoid Culturing Market in Global (2023-2034)
  • Table 2: Automated Organoid Culturing Market in Global by Product and Services (2023-2034)
  • Table 3: Automated Organoid Culturing Market in Global by Organoid (2023-2034)
  • Table 4: Automated Organoid Culturing Market in Global by Application (2023-2034)
  • Table 5: Automated Organoid Culturing Market in Global by End-Users (2023-2034)
  • Table 6: Automated Organoid Culturing Market in Global by Geography (2023-2034)
  • Table 7: Automated Organoid Culturing Market in North America (2023-2034)
  • Table 8: Automated Organoid Culturing Market in the United States (2023-2034)
  • Table 9: Automated Organoid Culturing Market in Canada (2023-2034)
  • Table 10: Automated Organoid Culturing Market in Mexico (2023-2034)
  • Table 11: Automated Organoid Culturing Market in Europe (2023-2034)
  • Table 12: Automated Organoid Culturing Market in France (2023-2034)
  • Table 13: Automated Organoid Culturing Market in Germany (2023-2034)
  • Table 14: Automated Organoid Culturing Market in United Kingdom (2023-2034)
  • Table 15: Automated Organoid Culturing Market in Italy (2023-2034)
  • Table 16: Automated Organoid Culturing Market in Spain (2023-2034)
  • Table 17: Automated Organoid Culturing Market in the Rest of Europe (2023-2034)
  • Table 18: Automated Organoid Culturing Market in Asia-Pacific (2023-2034)
  • Table 19: Automated Organoid Culturing Market in China (2023-2034)
  • Table 20: Automated Organoid Culturing Market in Japan (2023-2034)
  • Table 21: Automated Organoid Culturing Market in India (2023-2034)
  • Table 22: Automated Organoid Culturing Market in Australia (2023-2034)
  • Table 23: Automated Organoid Culturing Market in South Korea (2023-2034)
  • Table 24: Automated Organoid Culturing Market in Rest of Asia-Pacific (2023-2034)
  • Table 25: Automated Organoid Culturing Market in the Rest of the World (2023-2034)
  • Table 26: Automated Organoid Culturing Market in the Middle East (2023-2034)
  • Table 27: Automated Organoid Culturing Market in Africa (2023-2034)
  • Table 28: Automated Organoid Culturing Market in South America (2023-2034)
  • Table 29: Competitive Landscape
  • Table 30: Startup Funding & Investment Trends

List of Figures

  • Figure 1: Automated Organoid Culturing Market Drivers
  • Figure 2: Automated Organoid Culturing Market Restraints
  • Figure 3: Automated Organoid Culturing Market Opportunities
  • Figure 4: AI-Powered Innovations in Automated Organoid Culturing Market
  • Figure 5: US Tariff Impact on Automated Organoid Culturing Market
  • Figure 6: Regulatory Analysis (US, EU, Japan, China)
  • Figure 7: Porter's Five Forces Analysis
  • Figure 8: Competitive Analysis
  • Figure 9: Automated Organoid Culturing Market in Global (2023-2034)
  • Figure 10: Automated Organoid Culturing Market in Global by Product and Services (2023-2034)
  • Figure 11: Automated Organoid Culturing Market in Global by Organoid (2023-2034)
  • Figure 12: Automated Organoid Culturing Market in Global by Application (2023-2034)
  • Figure 13: Automated Organoid Culturing Market in Global by End-Users (2023-2034)
  • Figure 14: Automated Organoid Culturing Market in Global by Geography (2023-2034)
  • Figure 15: Automated Organoid Culturing Market in North America (2023-2034)
  • Figure 16: Automated Organoid Culturing Market in the United States (2023-2034)
  • Figure 17: Automated Organoid Culturing Market in Canada (2023-2034)
  • Figure 18: Automated Organoid Culturing Market in Mexico (2023-2034)
  • Figure 19: Automated Organoid Culturing Market in Europe (2023-2034)
  • Figure 20: Automated Organoid Culturing Market in France (2023-2034)
  • Figure 21: Automated Organoid Culturing Market in Germany (2023-2034)
  • Figure 22: Automated Organoid Culturing Market in United Kingdom (2023-2034)
  • Figure 23: Automated Organoid Culturing Market in Italy (2023-2034)
  • Figure 24: Automated Organoid Culturing Market in Spain (2023-2034)
  • Figure 25: Automated Organoid Culturing Market in the Rest of Europe (2023-2034)
  • Figure 26: Automated Organoid Culturing Market in Asia-Pacific (2023-2034)
  • Figure 27: Automated Organoid Culturing Market in China (2023-2034)
  • Figure 28: Automated Organoid Culturing Market in Japan (2023-2034)
  • Figure 29: Automated Organoid Culturing Market in India (2023-2034)
  • Figure 30: Automated Organoid Culturing Market in Australia (2023-2034)
  • Figure 31: Automated Organoid Culturing Market in South Korea (2023-2034)
  • Figure 32: Automated Organoid Culturing Market in Rest of Asia-Pacific (2023-2034)
  • Figure 33: Automated Organoid Culturing Market in the Rest of the World (2023-2034)
  • Figure 34: Automated Organoid Culturing Market in the Middle East (2023-2034)
  • Figure 35: Automated Organoid Culturing Market in Africa (2023-2034)
  • Figure 36: Automated Organoid Culturing Market in South America (2023-2034)
  • Figure 39: Competitive Landscape
  • Figure 40: Startup Funding & Investment Trends